Catalent, Nanoscope Expand Partnership for Gene Therapy Commercialization

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease-agnostic, vision-restoring therapies for patients with photoreceptor loss due to retinal degeneration, announced an expanded partnership to support late-phase clinical and commercial supply of Nanoscope’s lead optogenetic gene therapy, MCO-010.

Under the expanded partnership, Catalent will provide commercial-compliant packaging and distribution for MCO-010 and has secured the commercial packaging validation program to support Nanoscope’s Biologics License Application (BLA). A rolling submission with the U.S. Food and Drug Administration (FDA) is currently underway.

“Catalent is pleased to expand our collaboration with Nanoscope as MCO-010 advances toward potential commercialization,” said Ricky Hopson, Group President, Clinical & Specialty Services and Chief of Staff. “Catalent is committed to supporting Nanoscope at every stage of the journey to bring this innovative therapy to the market and help make Nanoscope’s mission of vision restoration a reality for patients around the globe.”